1. Improving Overall Health

2. Glycemic Control and Its Effects on Outcomes

3. Individualizing T2D Treatment

4. Lifestyle Management

5. Decreasing CV Risk in Patients With T2D and Known CV Risk

6. Glycemic and Extraglycemic Effects of New Therapeutic Classes for T2D

7. EMPA-REG OUTCOME and What's to Come

8. GLP-1 Receptor Agonist CVOTs LEADER, SUSTAIN-6, ELIXA

9. CV Safety of DPP-4 Inhibitors

10. Clinical Implications of the CVD-REAL Observational Study

11. Safety of New Therapeutic Agents for T2D

12. Concluding Remarks

13. Abbreviations

14. Abbreviations (cont)